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LETTERS TO THE EDITO R
Use of antimalarial drugs in Zimbabwe
Dear sir,
Malaria is a world-wide problem which is estimated to 
contribute to 2.3% of global disease1 and is an increasing 
problem, particularly in developing countries.2 In 
Zimbabwe, the development of widespread resistance to 
antimalarial drugs has been prevented through a 
comprehensive national malaria strategy including the 
development and enforcement of national guidelines for 
the prophylaxis and treatment of malaria. However, in 
recent years numerous anecdotal accounts have circulated 
in the private sector of failure of malaria chemoprophylaxis 
and treatment. This study set out to explore the use of 
antimalarial drug products amongst doctors and pharmacists 
so as to identify potential problems requiring further 
investigation.
A cross sectional survey (March to August 1998) using 
pre-tested, self-administered questionnaires was performed. 
Respondents were asked to report on, amongst other things, 
first and second choices for prophylaxis and treatment 
(doctors only) of m alaria, and experience with 
“breakthrough” cases (prophylaxis failure). Questionnaires 
were posted to random samples of 70 doctors (10% sample) 
and 100 pharmacies (5% sample) throughout Zimbabwe. 
There was no follow up to increase response rates.
Table 1: Demographic characteristics of respondents.
Sex n (%) A ge D istribution (yrs)
M ale Fem ale 21-30 31-40 41-50 50+
D o c to rs 11 (1 0 0 .0 ) 0  (0 .0 ) 1 3 4 3
P h a rm a c is ts 1 0  (5 2 .6 ) 9  (4 7 .4 ) 6  8 2 3
Responses were received from 11 doctors (15.7% 
response) and 19 pharmacists (19.0%). Demographic details 
of the respondents are shown in Table I. Amongst the 11 
medical respondents, seven reported their first line choice 
in chemoprophylaxis against malaria as'the pyrimethamine/ 
dapsone combination (P/D; lOOmg dapsone with 12,5 mg 
pyrimethamine) taken weekly (Figure I). Pyrimethamine/ 
dapsone taken together with chloroquine (150 mg base) on 
a weekly basis was reported by two doctors. As their 
second line drug, four reported that they recommended 
chloroquine (150 mg base weekly) and proguanil (100 mg 
daily) (Figure II).
For the treatment of uncomplicated malaria, chloroquine 
was the drug of choice for nine respondents, with others 
recommending halofantrine, pyrimethamine/sulfadoxine 
(P/S) or quinine with tetracycline. Quinine was most 
commonly used for complicated malaria. Four doctors 
would wait for blood test results before initiating therapy. 
Seven of the doctors reported seeing cases of breakthrough 
malaria to P/D, chloroquine and. chloroquine/proguanil.
Most suspected cases (63.7%) were apparently contracted 
in the Zambezi Valley and Kariba. Ten of the respondents 
had seen malaria resistant to treatment, usually to 
chloroquine (over 90% of cases) but also to P/S and 
halofantrine. Only one respondent had sent in a blood 
sample to Blair Research Laboratories to confirm resistance. 
Biomedical journals, textbooks and lecture meetings were 
the most important sources of information about 
antimalarial drugs.
Figure l: First choice malaria prophylaxis recommended 
by respondents.
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Figure II: Second choice malaria prophylaxis 
recommended by respondents.
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From the pharmacist’s questionnaire, the most frequently 
recommended drug for malaria prophylaxis was P/D (12 
respondents) followed by P/D plus chloroquine (Figure I). 
As a second line prophylactic drug, almost three quarters 
recommended chloroquine plus proguanil (Figure II). With 
regard to recommendations for the use of mosquito nets, 
wearing protective clothing and the use of repellents, nine 
of the pharmacists mentioned all three of the non- 
pharmacological methods whilst the remainder mentioned 
only two. When posed with a situation of a client 
approaching them complaining of malaria, all but one 
would recommend over-the-counter treatment rather than . 
referral. The majority of breakthrough cases had occurred
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whilst the client was taking P/D (82.4%) with the remainder 
occurring with chloroquine alone or chloroquine plus 
proguanil. Fifteen of the pharmacists believed that there 
was resistance to the malaria prophylactic drugs. The most 
important sources of information were the same as for the 
doctors.
Although bias is present with the low response rate and 
self-reported rather than actual practice, the information 
presented is still useful in assessing knowledge and use of 
antimalarial drugs in Zimbabwe. Only about 60% of 
doctors and pharmacists followed the national standard 
treatment guidelines (STGs) for malaria chemoprophylaxis 
as found in EDLIZ 1994.5 For second choice prophylaxis, 
pharmacist recommendations were generally in line with 
the STGs but doctors showed great variability. Of particular 
concern is that some recommended single drugs with 
resistance to those already documented in Zimbabwe.6 The 
variation from the STGs may relate to concerns about drug 
resistance since most had reported experience with this.
The majority of doctors followed the national malaria 
treatment guidelines for treatment of uncomplicated malaria 
(chloroquine), but there was more, variability for 
complicated malaria. This may reflect concerns about the 
effect of treatment failure in severe cases. Only one doctor 
had sent a blood sample to the Blair Research Laboratories 
to confirm resistance, which affects the quality of the data 
which the national surveillance centre is able to compile 
and disseminate.
With most pharmacists willing to offer malaria treatment 
based, on clinical presentation, their ability to recognise 
malaria cases needs to be assessed and the national malaria 
committee must decide what approach they would like 
pharmacists to follow. The role of ancillary pharmacy staff 
should also be examined.
In conclusion* this study found that whilst the majority of 
medical practitioners and pharmacists seem to adhere to 
malaria policy guidelines, there would appear to be concerns 
of malaria resistance which need to be addressed. Studies 
need to be designed to investigate actual prescribing patterns 
and information provision by these health care providers 
with regard to malaria.-
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